SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-017866
Filing Date
2023-05-04
Accepted
2023-05-04 16:12:48
Documents
70
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20230331.htm   iXBRL 10-Q 2695892
2 EX-31.1 ntla-ex31_1.htm EX-31 17144
3 EX-31.2 ntla-ex31_2.htm EX-31 17161
4 EX-32.1 ntla-ex32_1.htm EX-32 10842
  Complete submission text file 0000950170-23-017866.txt   10406255

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ntla-20230331_cal.xml EX-101.CAL 41909
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20230331.xsd EX-101.SCH 54782
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20230331_pre.xml EX-101.PRE 352576
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ntla-20230331_def.xml EX-101.DEF 220677
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20230331_lab.xml EX-101.LAB 470546
64 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20230331_htm.xml XML 2307727
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 23888858
SIC: 2835 In Vitro & In Vivo Diagnostic Substances